Abstract
Under physiological conditions, nitric oxide (NO) is produced in the vasculature mainly by the endothelial NO synthase (eNOS). This endothelium-derived NO is a protective molecule with antihypertensive, antithrombotic and anti-atherosclerotic properties. Cardiovascular risk factors such as hypertension, hypercholesterolemia, cigarette smoking and diabetes mellitus induce oxidative stress mostly by stimulation of the NADPH oxidase. Overproduction of reactive oxygen species leads to oxidation of tetrahydrobiopterin (BH4), the essential cofactor of eNOS. In BH4 deficiency, oxygen reduction uncouples from NO synthesis, thereby converting eNOS to a superoxide- producing enzyme. Consequently, NO production is reduced and the pre-existing oxidative stress is enhanced, which contribute significantly to cardiovascular pathology. Therefore, pharmacological approaches that prevent eNOS uncoupling are of therapeutic interest. Among the drugs currently in clinical use, the renin inhibitor aliskiren, angiotensin-converting enzyme inhibitors, AT1 receptor blockers, the selective aldosterone antagonist eplerenone, statins, nebivolol and pentaerithrityl tetranitrate have been shown to have the potential to prevent or reverse eNOS uncoupling under experimental conditions. Resveratrol, BH4, sepiapterin, folic acid and AVE3085 have also been shown to recouple eNOS and improve endothelial function. The long-term benefit of these compounds, however, is still controversial.
Keywords: Nitric oxide, endothelial NO synthase, eNOS uncoupling, NADPH oxidase; oxidative stress.
Current Pharmaceutical Design
Title:Pharmacological Prevention of eNOS Uncoupling
Volume: 20 Issue: 22
Author(s): Huige Li and Ulrich Forstermann
Affiliation:
Keywords: Nitric oxide, endothelial NO synthase, eNOS uncoupling, NADPH oxidase; oxidative stress.
Abstract: Under physiological conditions, nitric oxide (NO) is produced in the vasculature mainly by the endothelial NO synthase (eNOS). This endothelium-derived NO is a protective molecule with antihypertensive, antithrombotic and anti-atherosclerotic properties. Cardiovascular risk factors such as hypertension, hypercholesterolemia, cigarette smoking and diabetes mellitus induce oxidative stress mostly by stimulation of the NADPH oxidase. Overproduction of reactive oxygen species leads to oxidation of tetrahydrobiopterin (BH4), the essential cofactor of eNOS. In BH4 deficiency, oxygen reduction uncouples from NO synthesis, thereby converting eNOS to a superoxide- producing enzyme. Consequently, NO production is reduced and the pre-existing oxidative stress is enhanced, which contribute significantly to cardiovascular pathology. Therefore, pharmacological approaches that prevent eNOS uncoupling are of therapeutic interest. Among the drugs currently in clinical use, the renin inhibitor aliskiren, angiotensin-converting enzyme inhibitors, AT1 receptor blockers, the selective aldosterone antagonist eplerenone, statins, nebivolol and pentaerithrityl tetranitrate have been shown to have the potential to prevent or reverse eNOS uncoupling under experimental conditions. Resveratrol, BH4, sepiapterin, folic acid and AVE3085 have also been shown to recouple eNOS and improve endothelial function. The long-term benefit of these compounds, however, is still controversial.
Export Options
About this article
Cite this article as:
Li Huige and Forstermann Ulrich, Pharmacological Prevention of eNOS Uncoupling, Current Pharmaceutical Design 2014; 20 (22) . https://dx.doi.org/10.2174/13816128113196660749
DOI https://dx.doi.org/10.2174/13816128113196660749 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Ghrelin in Drug Abuse and Reward-Relevant Behaviors: A Burgeoning Field and Gaps in the Literature
Current Drug Abuse Reviews Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update
Current Diabetes Reviews Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications
Current Diabetes Reviews Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
Current Topics in Medicinal Chemistry Clearance of Amyloid-β Peptide by Neuronal and Non-Neuronal Cells: Proteolytic Degradation by Secreted and Membrane associated Proteases
Current Neurovascular Research Psychopharmacological Interventions for Adolescents with Eating Disorders
Adolescent Psychiatry The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Patenting the Gene-Hubs of Endoplasmic Reticulum Stress: The Systems Biology Approach
Recent Patents on Biotechnology Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Rapid Estrogen Signaling in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mechanistic Insights Into Diabetes Mellitus and Oxidative Stress
Current Medicinal Chemistry A Review of the Most Important Classes of Serine Protease Inhibitors in Insects and Leeches
Medicinal Chemistry Reviews - Online (Discontinued) Editorial [Hot topic:Expression and Refolding Technologies for Production of Recombinant Proteins (Guest Editors: Tsutomu Arakawa and Kouhei Tsumoto)]
Current Pharmaceutical Biotechnology Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology